Fig. 3From: Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS databaseProportion of deaths among adverse outcomes associated with three anti-HER-2 agentsBack to article page
